Cypress Sued Over Unapproved Cold Medication

Law360, New York (April 15, 2011, 6:01 PM EDT) -- Generic-drug maker Cypress Pharmaceutical Inc. was socked with a proposed class action Friday in Pennsylvania for allegedly selling a cold, flu and allergy medication that never received approval from the U.S. Food and Drug Administration.

The breach of contract and breach of warranty suit, lodged in the U.S. District Court for the Eastern District of Pennsylvania, said Cypress' over-the-counter Ceron DM syrup — also marketed as Robitussin Cough & Allergy, Rondec DM and Norel DM — was unregulated, potentially unsafe, ineffective and not suitable for consumption....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MCLEOD v. CYPRESS PHARMACEUTICAL, INC.


Case Number

2:11-cv-02601

Court

Pennsylvania Eastern

Nature of Suit

Contract Product Liability

Judge

THOMAS N. ONEILL, JR

Date Filed

April 14, 2011

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.